PSY38 A UK Based Cost-Effectiveness Analysis of Dasatinib (Sprycel) 100mg Daily Compared to Imatinib (Glivec) 400mg Daily in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML)
Jun 1, 2012, 00:00
10.1016/j.jval.2012.03.572
https://www.valueinhealthjournal.com/article/S1098-3015(12)00637-7/fulltext
Title :
PSY38 A UK Based Cost-Effectiveness Analysis of Dasatinib (Sprycel) 100mg Daily Compared to Imatinib (Glivec) 400mg Daily in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)00637-7&doi=10.1016/j.jval.2012.03.572
First page :
A105
Section Title :
Systemic Disorders/Conditions
Open access? :
No
Section Order :
38